Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 3
2014 1
2015 2
2016 2
2017 2
2018 3
2019 5
2022 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Chronic Leukemia"
Page 1
Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A, Gaio M, Liguori V, Cagnotta C, Paolino D, Paolisso G, Castaldo G, Nicoletti GF, Rossi F, Capuano A, Rafaniello C. Zinzi A, et al. Pharmacol Res. 2023 Apr;190:106742. doi: 10.1016/j.phrs.2023.106742. Epub 2023 Mar 22. Pharmacol Res. 2023. PMID: 36963592 Free article. Review.
CAR-T cell therapy is currently being used for the treatment of relapsed/refractory (r/r) B-cell malignancies including Acute Lymphoblastic Leukemia, Large B-Cell Lymphoma, Follicular Lymphoma, Multiple Myeloma and Mantle Cell Lymphoma. ...
CAR-T cell therapy is currently being used for the treatment of relapsed/refractory (r/r) B-cell malignancies including Acute Lymphob …
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ, Grimshaw AA, Silberstein J, Murdaugh D, Wildes TM, Rosko AE, Giri S. Grant SJ, et al. Transplant Cell Ther. 2022 Jun;28(6):294-302. doi: 10.1016/j.jtct.2022.03.006. Epub 2022 Mar 11. Transplant Cell Ther. 2022. PMID: 35288347 Free PMC article. Review.
Chimeric antigen receptor (CAR) T cell therapy is a novel therapy for patients with relapsed or refractory hematologic malignancies. Most CAR T cell therapy recipients will experience clinical features of the immune effector cell-associated neurotoxicity syndrome (ICANS), …
Chimeric antigen receptor (CAR) T cell therapy is a novel therapy for patients with relapsed or refractory hematologic malignancies. …
Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.
Hill QA, Hill A, Berentsen S. Hill QA, et al. Blood Adv. 2019 Jun 25;3(12):1897-1906. doi: 10.1182/bloodadvances.2019000036. Blood Adv. 2019. PMID: 31235526 Free PMC article.
In this systematic review of literature from January 2006 to December 2015, we assessed heterogeneity in the definition of AIHA and its subtypes, refractory disease, disease phase, severity, criteria for treatment response, and response durability. ...A lower threshold for …
In this systematic review of literature from January 2006 to December 2015, we assessed heterogeneity in the definition of AIHA and its subt …
Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
Liang L, Zhao M, Zhu YC, Hu X, Yang LP, Liu H. Liang L, et al. Ann Hematol. 2016 Sep;95(9):1473-82. doi: 10.1007/s00277-016-2719-6. Epub 2016 Jun 21. Ann Hematol. 2016. PMID: 27329288 Review.
Therapeutic results of relapsed/refractory chronic lymphocytic leukemia (CLL) are very disappointing at present. Lenalidomide has been proved to be effective for relapsed/refractory CLL as a single agent or in combination with various chemo-immunothera …
Therapeutic results of relapsed/refractory chronic lymphocytic leukemia (CLL) are very disappointing at present. Lenali …
Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis.
Police RL, Trask PC, Wang J, Olivares R, Khan S, Abbe A, Colosia A, Njue A, Sherrill B, Ruiz-Soto R, Kaye JA, Hamadani M. Police RL, et al. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207. doi: 10.1016/j.clml.2014.09.008. Epub 2014 Oct 2. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25445467 Review.
This systematic literature review with meta-analysis was conducted on the clinical efficacy and safety of interventions used in the treatment of chronic lymphocytic leukemia (CLL). We systematically searched databases (PubMed, Cochrane Library, and Embase; 1997 to A …
This systematic literature review with meta-analysis was conducted on the clinical efficacy and safety of interventions used in the treatmen …
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Nguyen TT, Thanh Nhu N, Tran VK, Van Cau N, Lin CF. Nguyen TT, et al. J Immunother. 2023 Oct 1;46(8):299-309. doi: 10.1097/CJI.0000000000000471. Epub 2023 May 23. J Immunother. 2023. PMID: 37216406
Treatment with chemoimmunotherapy (CIT) is considered an appropriate front-line treatment option for chronic lymphocytic leukemia (CLL). However, outcomes remain suboptimal. Bruton tyrosine kinase inhibitor (BTKi) combined with anti-CD20 antibody is an effective tre …
Treatment with chemoimmunotherapy (CIT) is considered an appropriate front-line treatment option for chronic lymphocytic leukemia …
Safety and efficacy of dual PI3K-delta, gamma inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z, Zhou H, Xu J, Wang J, Niu T. Wang Z, et al. Front Immunol. 2023 Jan 4;13:1070660. doi: 10.3389/fimmu.2022.1070660. eCollection 2022. Front Immunol. 2023. PMID: 36685572 Free PMC article.
This systematic review and meta-analysis aimed to evaluate the safety and efficacy of duvelisib in treating different relapsed or refractory (RR) lymphoid neoplasm types. METHODS: We searched prospective clinical trials from PUBMED, EMBASE, Cochrane Library, and ClinicalTr …
This systematic review and meta-analysis aimed to evaluate the safety and efficacy of duvelisib in treating different relapsed or refract …
The value of rituximab for the treatment of fludarabine-refractory chronic lymphocytic leukemia: a systematic review and qualitative analysis of the literature.
Lepretre S, Jäger U, Janssens A, Leblond V, Nikitin E, Robak T, Wendtner CM. Lepretre S, et al. Leuk Lymphoma. 2012 May;53(5):820-9. doi: 10.3109/10428194.2011.631636. Epub 2011 Dec 13. Leuk Lymphoma. 2012. PMID: 21992675 Review.
The increase of fludarabine-resistant chronic lymphocytic leukemia (CLL) presents a new treatment challenge. The aim of this review is to evaluate the efficacy and safety of rituximab for patients with fludarabine-refractory CLL. Medline, Embase, The Cochrane …
The increase of fludarabine-resistant chronic lymphocytic leukemia (CLL) presents a new treatment challenge. The aim of this r …
Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review.
Wen Y, Meng L, Zhang X, Gao Q. Wen Y, et al. Expert Rev Hematol. 2022 Sep;15(9):849-856. doi: 10.1080/17474086.2022.2110062. Epub 2022 Aug 9. Expert Rev Hematol. 2022. PMID: 35920616
BACKGROUND: Phosphatidylinositol 3-kinase (PI3K) inhibitors demonstrate promising effects in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL). Emerging evidence of the therapeutic effects of the PI3K inhibitors in various aspects remain …
BACKGROUND: Phosphatidylinositol 3-kinase (PI3K) inhibitors demonstrate promising effects in the treatment of relapsed/refractory …
A systematic review of economic evaluations for the pharmaceutical treatment of chronic lymphocytic leukemia and acute myeloid leukemia.
Gao L, Nguyen D, Lee P. Gao L, et al. Expert Rev Hematol. 2022 Sep;15(9):833-847. doi: 10.1080/17474086.2022.2125376. Expert Rev Hematol. 2022. PMID: 36102163
INTRODUCTION: No recent full-text-based systematic review has been published to examine economic evidence around acute myeloid leukemia (AML) or chronic lymphocytic leukemia (CLL) treatment. We aimed to perform a systematic review in this area. ...Most studie …
INTRODUCTION: No recent full-text-based systematic review has been published to examine economic evidence around acute myeloid leukemia …
23 results